Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cell Therapy for Multiple Sclerosis.

Pamela Sarkar1, Claire M Rice1, Neil J Scolding2

  • 1Institute of Clinical Neurosciences, Southmead Hospital, University of Bristol, L&R Building, Bristol, BS10 5NB, UK.

CNS Drugs
|April 12, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining Activity-Based Subgroups in Multiple Sclerosis: A Review and Framework Proposal.

European journal of neurology·2026
Same author

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

The 2024 McDonald criteria for the diagnosis of multiple sclerosis: implications for clinical practice.

Practical neurology·2026
Same author

Profiling peripheral blood oxidative stress in multiple sclerosis.

Multiple sclerosis and related disorders·2026
Same author

Cerebral venous sinus thrombosis complicating IgG4-related hypertrophic pachymeningitis.

Practical neurology·2025
Same author

Acute retinal necrosis associated with dimethyl fumarate.

Multiple sclerosis (Houndmills, Basingstoke, England)·2025
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Cell therapy offers promising treatments for multiple sclerosis (MS), particularly the progressive form. Research explores stem cell replacement, immune system modulation, and endogenous cell mobilization for MS repair and neuroprotection.

Area of Science:

  • Neuroscience
  • Immunology
  • Regenerative Medicine

Background:

  • Multiple sclerosis (MS) is a progressive neurodegenerative disease with limited treatment options.
  • Significant advancements in understanding MS biology and cell therapy development have occurred over two decades.
  • Current treatments for progressive MS are insufficient, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

  • To review progress in three distinct areas of cell therapy for multiple sclerosis.
  • To summarize the experimental background and clinical advancements in MS cell therapy.
  • To explore the potential of stem cells and endogenous cell populations in treating MS.

Main Methods:

  • Review of experimental and clinical data on cell therapy for MS.

Related Experiment Videos

  • Analysis of three distinct cell therapy approaches: stem cell replacement, hematopoietic stem cell transplantation, and endogenous stem cell mobilization.
  • Evaluation of myelin repair, immune modulation, and neuroprotection strategies.

    • Main Results:

    • Stem cell therapy aims to replace damaged oligodendrocytes for myelin repair.
    • Hematopoietic stem cell transplantation seeks to re-establish a non-pathogenic immune system.
    • Mobilization of endogenous stem cells exploits reparative and neuroprotective properties.

    Conclusions:

    • Cell therapy presents a promising avenue for treating multiple sclerosis, especially progressive forms.
    • Continued research in stem cell biology and clinical applications is crucial for MS treatment.
    • Multiple cell therapy strategies show potential for addressing MS pathology and improving patient outcomes.